The estimated Net Worth of Marshall Robert Ching is at least $24.9 Million dollars as of 21 April 2005. Marshall Ching owns over 600,000 units of Arrowhead Pharmaceuticals stock worth over $22,339,232 and over the last 20 years Marshall sold ARWR stock worth over $2,568,830.
Marshall has made over 4 trades of the Arrowhead Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Marshall sold 600,000 units of ARWR stock worth $1,962,000 on 21 April 2005.
The largest trade Marshall's ever made was selling 600,000 units of Arrowhead Pharmaceuticals stock on 21 April 2005 worth over $1,962,000. On average, Marshall trades about 122,667 units every 21 days since 2004. As of 21 April 2005 Marshall still owns at least 1,066,821 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Marshall Ching stock trades at the bottom of the page.
Marshall's mailing address filed with the SEC is C/O ARROWHEAD RESEARCH GROUP, 1118 EAST GREEN STREET, PASADENA, CA, 91106.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone, and Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: